Collaboration revenue (ASC 808)

A collaborative arrangement under ASC 808 is one where both parties are active participants and share in risks and rewards. Big pharma partnerships with joint steering committees, cost sharing, and profit splits usually qualify. The question is which parts of the arrangement involve a customer, because only those parts are revenue under ASC 606; the rest is presented based on the nature of the payment, often as a reduction of R&D expense or as other income.

ASU 2018-18 clarified that a unit of account within a collaboration is in the scope of ASC 606 only if the counterparty is a customer for that unit. A license granted to the partner is typically a customer transaction and produces revenue. Reimbursement of the company's share of joint development costs typically is not, and is presented as contra-expense with the policy disclosed.

The presentation choice changes reported revenue, R&D expense, and the burn narrative without changing cash. It needs a memo at signing and consistent application every quarter.